RSS feed

Publications by Marit Synnestvedt

37 publications found

Original articles

Helland T, Naume B, Hustad S, Bifulco E, Kvaløy JT, Saetersdal AB, Synnestvedt M, Lende TH, Gilje B, Mjaaland I, Weyde K, Blix ES, Wiedswang G, Borgen E, Hertz DL, Janssen EAM, Mellgren G, Søiland H (2020)
Low Z-4OHtam concentrations are associated with adverse clinical outcome among early stage premenopausal breast cancer patients treated with adjuvant tamoxifen
Mol Oncol, 15 (4), 957-967
DOI 10.1002/1878-0261.12865, PubMed 33252186

Borgen E, Rypdal MC, Sosa MS, Renolen A, Schlichting E, Lønning PE, Synnestvedt M, Aguirre-Ghiso JA, Naume B (2018)
NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients
Breast Cancer Res, 20 (1), 120
DOI 10.1186/s13058-018-1049-0, PubMed 30322396

Chudgar AV, Conant EF, Weinstein SP, Keller BM, Synnestvedt M, Yamartino P, McDonald ES (2017)
Assessment of disease extent on contrast-enhanced MRI in breast cancer detected at digital breast tomosynthesis versus digital mammography alone
Clin Radiol, 72 (7), 573-579
DOI 10.1016/j.crad.2017.02.013, PubMed 28318506

Egeland EV, Boye K, Park D, Synnestvedt M, Sauer T, Oslo Breast Cancer Consortium (OSBREAC), Naume B, Borgen E, Mælandsmo GM (2017)
Prognostic significance of S100A4-expression and subcellular localization in early-stage breast cancer
Breast Cancer Res Treat, 162 (1), 127-137
DOI 10.1007/s10549-016-4096-1, PubMed 28058579

Naume B, Synnestvedt M, Falk RS, Wiedswang G, Weyde K, Risberg T, Kersten C, Mjaaland I, Vindi L, Sommer HH, Sætersdal AB, Rypdal MC, Bendigtsen Schirmer C, Wist EA, Borgen E (2014)
Clinical outcome with correlation to disseminated tumor cell (DTC) status after DTC-guided secondary adjuvant treatment with docetaxel in early breast cancer
J Clin Oncol, 32 (34), 3848-57
DOI 10.1200/JCO.2014.56.9327, PubMed 25366688

Gilje B, Nordgård O, Tjensvoll K, Borgen E, Synnestvedt M, Smaaland R, Naume B (2014)
Comparison of molecular and immunocytochemical methods for detection of disseminated tumor cells in bone marrow from early breast cancer patients
BMC Cancer, 14, 514
DOI 10.1186/1471-2407-14-514, PubMed 25023626

Synnestvedt M, Borgen E, Schlichting E, Schirmer CB, Renolen A, Giercksky KE, Nesland JM, Naume B (2013)
Disseminated tumour cells in the bone marrow in early breast cancer: morphological categories of immunocytochemically positive cells have different impact on clinical outcome
Breast Cancer Res Treat, 138 (2), 485-97
DOI 10.1007/s10549-013-2439-8, PubMed 23456230

Synnestvedt M, Borgen E, Wist E, Wiedswang G, Weyde K, Risberg T, Kersten C, Mjaaland I, Vindi L, Schirmer C, Nesland JM, Naume B (2012)
Disseminated tumor cells as selection marker and monitoring tool for secondary adjuvant treatment in early breast cancer. Descriptive results from an intervention study
BMC Cancer, 12, 616
DOI 10.1186/1471-2407-12-616, PubMed 23259667

Dhakal HP, Naume B, Synnestvedt M, Borgen E, Kaaresen R, Schlichting E, Wiedswang G, Bassarova A, Holm R, Giercksky KE, Nesland JM (2012)
Expression of cyclooxygenase-2 in invasive breast carcinomas and its prognostic impact
Histol Histopathol, 27 (10), 1315-25
DOI 10.14670/HH-27.1315, PubMed 22936450

Synnestvedt M, Borgen E, Russnes HG, Kumar NT, Schlichting E, Giercksky KE, Kåresen R, Nesland JM, Naume B (2012)
Combined analysis of vascular invasion, grade, HER2 and Ki67 expression identifies early breast cancer patients with questionable benefit of systemic adjuvant therapy
Acta Oncol, 52 (1), 91-101
DOI 10.3109/0284186X.2012.713508, PubMed 22934555

Dhakal HP, Naume B, Synnestvedt M, Borgen E, Kaaresen R, Schlichting E, Wiedswang G, Bassarova A, Holm R, Giercksky KE, Nesland JM (2012)
Expression of vascular endothelial growth factor and vascular endothelial growth factor receptors 1 and 2 in invasive breast carcinoma: prognostic significance and relationship with markers for aggressiveness
Histopathology, 61 (3), 350-64
DOI 10.1111/j.1365-2559.2012.04223.x, PubMed 22690749

Molloy TJ, Bosma AJ, Baumbusch LO, Synnestvedt M, Borgen E, Russnes HG, Schlichting E, van't Veer LJ, Naume B (2011)
The prognostic significance of tumour cell detection in the peripheral blood versus the bone marrow in 733 early-stage breast cancer patients
Breast Cancer Res, 13 (3), R61
DOI 10.1186/bcr2898, PubMed 21672237

Janni W, Vogl FD, Wiedswang G, Synnestvedt M, Fehm T, Jückstock J, Borgen E, Rack B, Braun S, Sommer H, Solomayer E, Pantel K, Nesland J, Friese K, Naume B (2011)
Persistence of disseminated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse--a European pooled analysis
Clin Cancer Res, 17 (9), 2967-76
DOI 10.1158/1078-0432.CCR-10-2515, PubMed 21415211

Kamalakaran S, Varadan V, Giercksky Russnes HE, Levy D, Kendall J, Janevski A, Riggs M, Banerjee N, Synnestvedt M, Schlichting E, Kåresen R, Shama Prasada K, Rotti H, Rao R, Rao L, Eric Tang MH, Satyamoorthy K, Lucito R, Wigler M, Dimitrova N, Naume B, Borresen-Dale AL, Hicks JB (2010)
DNA methylation patterns in luminal breast cancers differ from non-luminal subtypes and can identify relapse risk independent of other clinical variables
Mol Oncol, 5 (1), 77-92
DOI 10.1016/j.molonc.2010.11.002, PubMed 21169070

Effenberger KE, Borgen E, Eulenburg CZ, Bartkowiak K, Grosser A, Synnestvedt M, Kaaresen R, Brandt B, Nesland JM, Pantel K, Naume B (2010)
Detection and clinical relevance of early disseminated breast cancer cells depend on their cytokeratin expression pattern
Breast Cancer Res Treat, 125 (3), 729-38
DOI 10.1007/s10549-010-0911-2, PubMed 20449649

Dhakal HP, Bassarova A, Naume B, Synnestvedt M, Borgen E, Kaaresen R, Schlichting E, Wiedswang G, Giercksky KE, Nesland JM (2009)
Breast carcinoma vascularity: a comparison of manual microvessel count and Chalkley count
Histol Histopathol, 24 (8), 1049-59
DOI 10.14670/HH-24.1049, PubMed 19554512

Park D, Kåresen R, Naume B, Synnestvedt M, Beraki E, Sauer T (2009)
The prognostic impact of occult nodal metastasis in early breast carcinoma
Breast Cancer Res Treat, 118 (1), 57-66
DOI 10.1007/s10549-009-0340-2, PubMed 19219629

Dhakal HP, Naume B, Synnestvedt M, Borgen E, Kaaresen R, Schlichting E, Wiedswang G, Bassarova A, Giercksky KE, Nesland JM (2008)
Vascularization in primary breast carcinomas: its prognostic significance and relationship with tumor cell dissemination
Clin Cancer Res, 14 (8), 2341-50
DOI 10.1158/1078-0432.CCR-07-4214, PubMed 18413823

Naume B, Zhao X, Synnestvedt M, Borgen E, Russnes HG, Lingjaerde OC, Strømberg M, Wiedswang G, Kvalheim G, Kåresen R, Nesland JM, Børresen-Dale AL, Sørlie T (2007)
Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer
Mol Oncol, 1 (2), 160-71
DOI 10.1016/j.molonc.2007.03.004, PubMed 19383292

Synnestvedt M, Müller F, Gaustad P, Bucher A (2003)
Recurrent group A Streptococcal genital infection after Puerperal sepsis
Scand J Infect Dis, 35 (8), 509-10
DOI 10.1080/00365540310013261, PubMed 14514155

Wildemore JK, Schuchter L, Mick R, Synnestvedt M, Elenitsas R, Bedrosian I, Czerniecki BJ, Guerry D, Lessin SR, Elder DE, Bucky LP (2001)
Locally recurrent malignant melanoma characteristics and outcomes: a single-institution study
Ann Plast Surg, 46 (5), 488-94
DOI 10.1097/00000637-200105000-00006, PubMed 11352421

Christos PJ, Oliveria SA, Berwick M, Guerry D4th, Elder DE, Synnestvedt M, Fine JA, Barnhill RL, Halpern AC (2000)
Signs and symptoms of melanoma in older populations
J Clin Epidemiol, 53 (10), 1044-53
DOI 10.1016/s0895-4356(00)00224-9, PubMed 11027938

Mowad CM, Margolis DJ, Halpern AC, Suri B, Synnestvedt M, Guzzo CA (1998)
Hormonal influences on women with psoriasis
Cutis, 61 (5), 257-60
PubMed 9608337

Synnestvedt M, Meen O, Hofstad B (1997)
[Colorectal cancer. Location dependent symptoms?]
Tidsskr Nor Laegeforen, 117 (26), 3796-9
PubMed 9417683

Anbari KK, Schuchter LM, Bucky LP, Mick R, Synnestvedt M, Guerry D, Hamilton R, Halpern AC (1997)
Melanoma of unknown primary site: presentation, treatment, and prognosis--a single institution study. University of Pennsylvania Pigmented Lesion Study Group
Cancer, 79 (9), 1816-21
DOI 10.1002/(sici)1097-0142(19970501)79:9<1816::aid-cncr26>3.0.co;2-#, PubMed 9129001

Schuchter L, Schultz DJ, Synnestvedt M, Trock BJ, Guerry D, Elder DE, Elenitsas R, Clark WH, Halpern AC (1996)
A prognostic model for predicting 10-year survival in patients with primary melanoma. The Pigmented Lesion Group
Ann Intern Med, 125 (5), 369-75
DOI 10.7326/0003-4819-125-5-199609010-00003, PubMed 8702087

Baer SC, Schultz D, Synnestvedt M, Elder DE (1995)
Desmoplasia and neurotropism. Prognostic variables in patients with stage I melanoma
Cancer, 76 (11), 2242-7
DOI 10.1002/1097-0142(19951201)76:11<2242::aid-cncr2820761110>3.0.co;2-i, PubMed 8635027

Carey WP, Thompson CJ, Synnestvedt M, Guerry D, Halpern A, Schultz D, Elder DE (1994)
Dysplastic nevi as a melanoma risk factor in patients with familial melanoma
Cancer, 74 (12), 3118-25
DOI 10.1002/1097-0142(19941215)74:12<3118::aid-cncr2820741210>3.0.co;2-7, PubMed 7982177

Halpern AC, Guerry D, Elder DE, Trock B, Synnestvedt M, Humphreys T (1993)
Natural history of dysplastic nevi
J Am Acad Dermatol, 29 (1), 51-7
DOI 10.1016/0190-9622(93)70151-i, PubMed 8315078

Guerry D, Synnestvedt M, Elder DE, Schultz D (1993)
Lessons from tumor progression: the invasive radial growth phase of melanoma is common, incapable of metastasis, and indolent
J Invest Dermatol, 100 (3), 342S-345S
DOI 10.1111/1523-1747.ep12470248, PubMed 8440920

Halpern AC, Guerry D, Elder DE, Trock B, Synnestvedt M (1993)
A cohort study of melanoma in patients with dysplastic nevi
J Invest Dermatol, 100 (3), 346S-349S
DOI 10.1111/1523-1747.ep12470256, PubMed 8440922

Miller EJ, Daly JM, Synnestvedt M, Schultz D, Elder D, Guerry D (1992)
Loco-regional nodal relapse in melanoma
Surg Oncol, 1 (5), 333-40
DOI 10.1016/0960-7404(92)90033-h, PubMed 1341268

León P, Daly JM, Synnestvedt M, Schultz DJ, Elder DE, Clark WH (1991)
The prognostic implications of microscopic satellites in patients with clinical stage I melanoma
Arch Surg, 126 (12), 1461-8
DOI 10.1001/archsurg.1991.01410360031006, PubMed 1842174

Halpern AC, Guerry D, Elder DE, Clark WH, Synnestvedt M, Norman S, Ayerle R (1991)
Dysplastic nevi as risk markers of sporadic (nonfamilial) melanoma. A case-control study
Arch Dermatol, 127 (7), 995-9
PubMed 2064418

Clark WH, Elder DE, Guerry D, Braitman LE, Trock BJ, Schultz D, Synnestvedt M, Halpern AC (1989)
Model predicting survival in stage I melanoma based on tumor progression
J Natl Cancer Inst, 81 (24), 1893-904
DOI 10.1093/jnci/81.24.1893, PubMed 2593166

Zeitels J, LaRossa D, Hamilton R, Synnestvedt M, Schultz D (1988)
A comparison of local recurrence and resection margins for stage I primary cutaneous malignant melanomas
Plast Reconstr Surg, 81 (5), 688-93
DOI 10.1097/00006534-198805000-00007, PubMed 3362987

Other articles

Naume B, Zhao X, Synnestvedt M, Borgen E, Russnes HG, Lingjaerde OC, Stromberg M, Wiedswang G, Kvalheim G, Karesen R, Nesland JM, Borresen-Dale AL, Sorlie T (2010)
Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer (vol 1, pg 160, 2007)
Mol. Oncol., 4 (2), 169
DOI 10.1016/j.molonc.2010.01.003